Statins hold a significant investment
opportunity. In India, demand for statins
currently exceeds its production capacity. This
scenario is likely to intensify as more statins go
off patent. Further, with the increasing side
effects of other nonrelated
disease treatments
relating to cardiac aliments, the demand is
expected to rise further.
